Boundless Bio snags $100M to enter clinic and fight cancer by targeting circular DNA bits
Boundless Bio raised $100 million in a Series C round, the San Diego biotech said Tuesday, as it brings its unusual approach to fighting cancer into the clinic.
Since its founding in 2018, Boundless has been researching ways to target cancer cells that have little circular bits of DNA floating outside their chromosomes. Based on research by the biotech’s scientific co-founder Paul Mischel, these bizarre circles of DNA aren’t merely cellular debris but a culprit of cancer growth and resistance. Boundless’s lead drug candidate aims to kill these cancer cells by exploiting a special vulnerability in them, with Boundless dosing the first patient earlier this month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.